Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Exceptional extension!
Enjoy this offer
* See conditions under "Our services"

Valuation: Intervacc AB

Market Cap 45Cr 4.69Cr 4.1Cr 3.79Cr 3.54Cr 6.64Cr 443.3Cr 6.69Cr 18Cr 217.95Cr 18Cr 17Cr 757.17Cr P/E 2026 *
-5.51x
P/E 2027 * -5.51x
Enterprise Value 36Cr 3.79Cr 3.31Cr 3.06Cr 2.86Cr 5.36Cr 357.7Cr 5.4Cr 14Cr 175.87Cr 14Cr 14Cr 610.96Cr EV / Sales 2026 *
22.7x
EV / Sales 2027 * 11.8x
Free-Float
80.66%
Yield 2026 *
-
Yield 2027 * -
1 day+1.69%
1 week+0.15%
Current month+6.61%
1 month+4.09%
3 months+35.04%
6 months+46.24%
Current year+43.07%
1 week 1.28
Extreme 1.284
1.35
1 month 1.17
Extreme 1.17
1.38
Current year 0.57
Extreme 0.572
1.46
1 year 0.57
Extreme 0.572
1.46
3 years 0.57
Extreme 0.572
10.46
5 years 0.57
Extreme 0.572
84
10 years 0.57
Extreme 0.572
95.5
Manager TitleAgeSince
Chief Executive Officer 70 05/02/2026
Director of Finance/CFO - 06/02/2020
Chief Tech/Sci/R&D Officer - 11/06/2020
Director TitleAgeSince
Chairman 56 13/05/2026
Director/Board Member 72 01/01/2024
Director/Board Member 68 01/01/2025
Date Insider Type Main position Quantity % Market Cap.
23/25/23Free

Chief Financial Officer

9,29,208 1.2269%
17/25/17Sell

Chief Executive Officer

2,78,820 0.3681%
17/25/17Buy

Chief Executive Officer

1,35,000 0.1783%
Change 5-day change 1-year change 3-year change Capi.($)
+1.69%+0.15%+38.14%-77.78% 4.62Cr
+2.87%+4.57%+68.97%+119.22% 5.52TCr
+4.00%+7.51%+63.67%+68.77% 4.58TCr
-0.77%-0.67%-15.34%-15.95% 2.3TCr
+2.93%+1.17%-3.97%+384.78% 2.08TCr
+1.89%+4.40%+27.92%-16.98% 1.63TCr
+1.16%+3.86%+20.23%-36.42% 1.54TCr
-1.08%-3.11%+27.20%+158.30% 1.3TCr
+3.30%+15.02%+133.24%+273.89% 1.24TCr
+2.85%-4.94%+23.44% - 1.24TCr
Average +1.91%+2.90%+38.35%+95.31% 2.14TCr
Weighted average by Cap. +2.33%+3.92%+43.66%+108.88%

Financials

2026 *2027 *
Net sales 1.6Cr 16.66L 14.56L 13.46L 12.57L 23.59L 16Cr 23.77L 62.25L 7.74Cr 62.54L 61.19L 27Cr 3Cr 31.23L 27.29L 25.25L 23.56L 44.24L 30Cr 44.56L 1.17Cr 15Cr 1.17Cr 1.15Cr 50Cr
Net income -8.16Cr -84.96L -74.24L -68.67L -64.09L -1.2Cr -80Cr -1.21Cr -3.17Cr -39Cr -3.19Cr -3.12Cr -137.13Cr -8.33Cr -86.73L -75.78L -70.1L -65.43L -1.23Cr -82Cr -1.24Cr -3.24Cr -40Cr -3.26Cr -3.19Cr -139.99Cr
Net Debt -8.7Cr -90.58L -79.15L -73.21L -68.33L -1.28Cr -86Cr -1.29Cr -3.39Cr -42Cr -3.4Cr -3.33Cr -146.21Cr -9.6Cr -99.95L -87.34L -80.79L -75.4L -1.42Cr -94Cr -1.43Cr -3.74Cr -46Cr -3.75Cr -3.67Cr -161.33Cr
Logo Intervacc AB
Intervacc AB is a Sweden-based biotechnology company. It develops vaccines based on recombinant proteins for animal health care. The Company’s candidate vaccine against strangles Strangvac consists of soluble recombinant proteins and devoids any living infectious agent. The Company operates through two subsidiaries: Nord Vacc Lakemedel AB and Mybac-Vettech AB. Nord Vacc Lakemedel AB markets and distributes veterinary vaccines, pharmaceuticals and vitamins on European market. It offers assortment of fur animal vaccines, the Febrivac range, as well as swine vaccines for Swedish and Danish markets. Mybac-Vettech AB is a technology platform that focuses on diagnostics in the Swedish animal health market and offers bacteriological and mycological analyses.
Employees
16
Date Price Change Volume
22/26/22 1.322 kr +1.69% 5,12,115
18/26/18 1.300 kr -0.76% 5,38,301
17/26/17 1.310 kr -2.24% 3,75,168
16/26/16 1.340 kr +1.52% 4,04,662

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. IVACC Stock
-40%: Exceptional extension
d
:
:
SEIZE THE OFFER!